Grifols Announces Launch of the SPIRIT Registry at the NHF Annual Meeting

mia.burns

RESEARCH TRIANGLE PARK, N.C., Oct. 4, 2013 /CNW/ – Inc., a leading manufacturer of life-saving plasma protein therapies, today announced the of the (Study of Plasma-derived factor VIII/VWF in Immune toleRance Induction Therapy) for patients with hemophilia A at the National Hemophilia Foundation (NHF) in Anaheim, Calif. The SPIRIT will enroll U.S. patients with hemophilia A and inhibitors being treated with Grifols’ plasma-derived factor VIII/VWF product, ALPHANATE® (antihemophilic factor/von Willebrand factor complex [human]).

(Logo: http://photos.prnewswire.com/prnh/20110304/PH59473LOGO )

According to the registry’s lead investigator, Rebecca Kruse-Jarres, M.D., of Tulane University, this observational study fills an important void.

“There is not a lot of prospective data to help us understand how patients with inhibitors respond to treatment, especially as it relates to adherence and quality of life. The data from the SPIRIT registry will give us more information to treat our patients and should complement the ongoing RESIST study.”

Dr. Kruse-Jarres will present a poster at the NHF meeting that outlines the registry design.

“The SPIRIT registry is another example of Grifols’ commitment to the hemophilia community,” said Eva Bastida, Ph.D., Vice President of Scientific and Medical Affairs at Grifols. “We are happy to launch this initiative and further support efforts to provide information to hemophilia treaters.”

About ALPHANATE®

Indications
ALPHANATE® (antihemophilic factor/von Willebrand factor complex [human]) is indicated for:

Pharmalive – The Pulse of the Pharmaceutical Industry

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS